<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112632">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917266</url>
  </required_header>
  <id_info>
    <org_study_id>690</org_study_id>
    <nct_id>NCT01917266</nct_id>
  </id_info>
  <brief_title>Evaluation of Left Ventricular (LV) Lead Positioning Using MediGuide</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Cardiac Resynchronization Therapy(CRT) response in
      subjects with concordant versus discordant left ventricular (LV) lead position as compared
      to the site of latest mechanical activation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percent of patients with the left ventricle (LV) lead implanted at the site of latest mechanical activation</measure>
    <time_frame>This outcome measure will be assessed after an off-line analysis immediately after implant</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to Cardiac Resynchronization Therapy (CRT) as defined by percent change in end-systolic volume (ESV) at 6-month follow-up relative to baseline.</measure>
    <time_frame>6 months after implant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Concordant</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discordant</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Heart failure patients indicated for a Cardiac Resynchronization Therapy (CRT) device
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be scheduled to undergo implant of a Cardiac Resynchronization Therapy (CRT) system
             with approved standard indication per accepted guidelines as a new implant or an
             upgrade from an existing Implantable Cardioverter Defibrillator (ICD) or pacemaker
             with no prior left ventricular lead placement

          -  Be in sinus rhythm at the time of enrollment

          -  Have the ability to provide informed consent for study participation and be willing
             and able to comply with the Clinical Investigational Plan described evaluations

        Exclusion Criteria:

          -  Have persistent or permanent atrial fibrillation

          -  Be in New York Heart Association (NYHA) IV functional class

          -  Have prior left ventricular (LV) lead implant

          -  Be pacemaker-dependent

          -  Have a recent myocardial infarction within 40 days prior to enrollment

          -  Have undergone cardiac bypass surgery or coronary revascularization procedure within
             3 months prior to enrollment or be scheduled for such procedures in the following 7
             months

          -  Have had a recent Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
             within 3 months prior to enrollment

          -  Have had intravenous inotropic support in the last 30 days

          -  Exhibit Cheyne-Stokes respiration

          -  Be less than 18 years of age

          -  Be pregnant or planning to become pregnant during the duration of the investigation

          -  Be currently participating in any other clinical investigation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Hindricks, MD</last_name>
    <phone>+49 (341) 865 1413</phone>
    <email>hindg@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Hindricks, MD</last_name>
      <phone>+49 (341) 865 1413</phone>
      <email>hindg@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Gerhard Hindricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
